By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories today announced an agreement to be acquired by newly formed Nestle Health Science for an undisclosed amount.

Formed in January, Nestle Health Science is a wholly owned subsidiary of Nestle and is focused on developing science-based nutritional solutions for personalized medicine. According to Luis Cantarell, president and CEO of NHS, the deal is a "strategic move into gastrointestinal diagnostics."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.